🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Cardiovascular Outcomes Registry in Cardiogenic SHOCK (COR-SHOCK)

Recruitingn/aAges 18 Years - anyAllHospital de Santa Cruz, Portugal
NCT07597291 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this observational study is to evaluate the clinical outcomes and management approaches of cardiogenic shock throughout the years in adult patients admitted to a Cardiology Department. The main questions it aims to answer are: * How have management strategies and clinical outcomes for cardiogenic shock evolved over time? * How do clinical, laboratory, and advanced hemodynamic monitoring parameters relate to patient survival and overall prognosis in this population? Researchers will evaluate clinical data collected from 2017 onwards to see if therapeutic advancements and changes in clinical management over the years have led to improved patient survival and quality of care. Participants will: * Receive standard, routine medical care for cardiogenic shock as determined by their clinical team (no experimental interventions will be introduced). * Have their clinical, laborato

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: -Cardiogenic shock according to the following criteria: Cardiac disorder resulting in hypotension, defined as at least one of the following: * Systolic blood pressure (SBP) \<90 mmHg for ≥30 minutes, or * Requirement for vasopressors, inotropes, or mechanical circulatory support to maintain SBP ≥90 mmHg AND Evidence of tissue hypoperfusion, defined by the presence of at least one of the following: * Serum lactate \>2 mmol/L * Acute kidney injury and/or oliguria * Acute hepatic injury * Cool or mottled extremities * Altered mental status AND Clinical presentation judged to be primarily attributable to a cardiac etiology. Exclusion Criteria: * Age \< 18 years. * Other primary etiologies of shock at presentation (e.g., hypovolemic, hemorrhagic, septic, obstructive shock due to acute pulmonary embolism, or anaphylactic shock). * Refusal to participate in the study (applicable only to the prospective cohort).
💊

What it tests

  • Not listed
📍

Where

1 site
Unidade Local de Saúde de Lisboa Ocidental
Carnaxide, Portugal
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy